75% of Scleroderma Patients Show Meaningful Skin Improvement with Anabasum, Extension Study Shows
The thick skin that is a hallmark of scleroderma showed meaningful improvement in 75 percent of patients treated with Corbus Pharmaceuticals’ anabasum (JBT-101), according to initial results of an extension trial. Read more >>